Navigation Links
Under the right conditions, peptide blocks HIV infection at multiple points along the way
Date:7/24/2012

Human defensins, aptly named antimicrobial peptides, are made in immune system cells and epithelial cells (such as skin cells and cells that line the gut). One of these peptides, human neutrophil peptide 1, under certain circumstances hinders HIV infection, but exactly how it works remains unclear.

HIV entry into mature T-helper cells (cells essential to the immune system) proceeds by attachment of the virus to specific targets on T-helper cells, uptake of the virus, fusion of its envelope with the cell membranes, and release of the virus into the cells. In a forthcoming Journal of Biological Chemistry Paper of the Week, Gregory Melikyan at Emory University and colleagues investigated the ability of human neutrophil peptide 1 to impede each step of this process.

Using model cell lines, Melikyan's group showed that human neutrophil peptide 1 effectively prevented HIV entry into cells in multiple ways. First, human neutrophil peptide 1 reduced the number of specific targets on the cells available for HIV attachment. Second, this defensin also bound to specific targets on both the HIV envelope and the cells, preventing early and late stages of HIV-cell fusion. Finally, human neutrophil peptide 1 prevented HIV uptake into the cells without compromising the general ability of the cells to engulf other molecules.

While human neutrophil peptide 1 hinders HIV entry into cells under these lab conditions, it does not do so as effectively in the presence of serum -- meaning that it may not be as successful at blocking HIV in our bodies. But Melikyan's team showed that human neutrophil peptide 1 remained attached to its specific targets in the presence of serum, despite its reduced efficacy. Their work suggests that the structure of human neutrophil peptide 1 is important for its anti-HIV activity, and they propose that serum may interfere with the ability of this defensin to form complexes, reducing its ability to block HIV.


'/>"/>
Contact: Angela Hopp
240-283-6614
American Society for Biochemistry and Molecular Biology
Source:Eurekalert

Page: 1 2

Related biology news :

1. U of Alberta researcher steps closer to understand autoimmune diseases
2. EU-funded study underlines importance of Congo Basin for global climate and biodiversity
3. MIT research: Study finds room to store CO2 underground
4. Specialization for underwater hearing by the tympanic middle ear of the turtle
5. Expedition to undersea mountain yields new information about sub-seafloor structure
6. Penn research points to new way of preserving fertility for boys undergoing cancer treatment
7. Planet under Pressure conference, London: Final statement
8. Under climate change, winners and losers on the coral reef
9. Study amplifies understanding of hearing in baleen whales
10. New genetically engineered mice aid understanding of incurable neuromuscular disease
11. Effect of chronic exposure to chemicals used as weapons, pesticides under study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... In Brazil , cloud computing ... these solutions and 42 percent planning to invest in them ... percent of the companies will be investing in these solutions ... companies in the region are currently opting for the private ... command significant attention in the coming years. This trend is ...
(Date:3/4/2015)... 2015 Research and Markets ( ... "Global Biometrics Market Forecast and Opportunities, 2020" ... market for biometric authentication systems is projected to ... 2020 The driving forces for this ... government projects and constant development in technology. In ...
(Date:3/3/2015)... , March 3, 2015 Cryoport, ... of advanced cryogenic logistics solutions for the ... stem cells, cell lines, clinical research organizations, ... today announced the expansion of its relationship ... ("Fred Hutch") Clinical Research Division with ...
Breaking Biology News(10 mins):Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3
... del Toro Research Station and Galeta Point Marine ... and a major coral bleaching event in the ... Atmospheric Administration, NOAA, issued an advisory in July ... Caribbean region, there had been no clear indication ...
... conference held in Brussels today, the International Osteoporosis Foundation (IOF), ... Group called on health care professionals and health policy officials ... call to action was made at the launch of a ... World Osteoporosis Day on October 20, 2010. Taking ...
... Gardeners could help maintain bumblebee populations by growing plants with ... to field observations of the common snapdragon, Antirrhinum majus ... Bees are important pollinators of crops as well as ... institute of the BBSRC, is committed to research that can ...
Cached Biology News:Smithsonian reports regional sea temperature rise and coral bleaching event in Western Caribbean 2IOF campaign puts spotlight on vastly under-diagnosed and under-treated spinal fractures 2Landing lights for bumblebees 2
(Date:3/5/2015)... March 05, 2015 North Carolina-based ... Noel, M.D., Professor of Medicine, Mayo Clinic College ... Board of Directors. , Entegrion’s Executive ... fortunate to have Dr. Noel, a distinguished physician ... organization, join Entegrion’s Board. His expertise in hematology ...
(Date:3/5/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/4ld5nw/mature_biotech ) has ... 2015: New Therapy Ventures Pave the Way for Success" ... biotech companies - Gilead (GILD), Amgen (AMGN), Biogen Idec ... a positive return and hence increased the interest of ... therapy/niche indication where the high treatment cost justifies the ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 The next ... have received the CE mark (European) approval. The CE ... Free Trade Association (EFTA) and the European Union. Following ... now been granted to implants supplied by the Turkey-based ... conditions. , Osimplant's Cervical Expandable Bladed HA PEEK ...
(Date:3/4/2015)... In an article published and posted online ... Security review the clinical aspects of diseases caused by ... The article, "Clinical Management of Potential Bioterrorism-Related Conditions," was ... the New England Journal of Medicine . ... and Tom Inglesby—review the clinical management of conditions resulting ...
Breaking Biology Technology:Entegrion Announces Appointment of Pierre Noel, MD, to Its Board of Directors 2Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 2Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 3Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 3Latest Clinical Information On Bioterrorism Threats 2
... 2011 Palatin Technologies, Inc. (NYSE Amex: PTN ... 23rd Annual OC Growth Stock Conference on Tuesday, March 15, ... held at the Ritz Carlton Laguna Niguel in Dana Point, ... Executive Officer of Palatin Technologies, will provide an update on ...
... 2011 AccessClosure, Inc., the U.S. market segment ... from the first published study* (Journal of NeuroInterventional ... different vascular closure devices (VCD) as the primary ... the discomfort associated with the Mynx 5F Vascular ...
... UBM Live and its sister company, UBM Japan ... and new developments taking place at the tenth anniversary of ... 18-20 April, 2011 at the Big Sight Exhibition Center in ... P-MEC Japan, which covers Pharma machinery and equipment, ICSE Japan, ...
Cached Biology Technology:Significant Reduction in Pain With the Mynx Vascular Closure Device Versus Angio-Seal Device 2Significant Reduction in Pain With the Mynx Vascular Closure Device Versus Angio-Seal Device 3UBM Announces Content for 10th Annual Japanese Pharma & Bio Events 2UBM Announces Content for 10th Annual Japanese Pharma & Bio Events 3UBM Announces Content for 10th Annual Japanese Pharma & Bio Events 4
Anti-MMP-19 (RASI), carboxy terminal region; rabbit host...
Rabbit anti MMP-13, Hinge Region MMP-13 Hinge Region...
Rabbit polyclonal to ATF4 (phospho S245) ( Abpromise for all tested applications). Antigen: Synthetic phosphopeptide derived from human ATF4 around the phosphorylation site of Serine 245. En...
Evolutionarily conserved signaling intermediate in Toll pathway...
Biology Products: